<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844155</url>
  </required_header>
  <id_info>
    <org_study_id>#ML25018</org_study_id>
    <secondary_id>Contract ID # 17908C</secondary_id>
    <nct_id>NCT00844155</nct_id>
  </id_info>
  <brief_title>Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit</brief_title>
  <official_title>A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (TamifluÂ®) in Patients in the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed pharmacokinetic study will test the hypothesis that in critically ill patients
      with respiratory failure requiring mechanical ventilation such as might be anticipated to be
      needed to treat patients with severe influenza pneumonia, oseltamivir administered enterally
      via nasogastric tube, with and without concomitant food or alimentation, will have similar
      oral bioavailability to that observed in ambulatory adults ill with influenza in whom
      oseltamivir therapy 75 mg BID is efficacious and well tolerated. Additionally, this
      experiment will test the hypothesis that increasing the dose (150 mg), with and without
      concomitant enteral feeding, will show a proportionate increase in bioavailability. Relative
      oral bioavailability will be assessed from plasma concentration vs. time over 12 hrs and
      urinary recovery of drug from 0 to 48 hrs after administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not required
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study has been withdrawn as the H1N1 epidemic made this study redundant
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oseltamivir administered enterally via nasogastric tube, with and without concomitant food or alimentation, will have similar oral bioavailability to that observed in ambulatory adults .</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test the hypothesis that increasing the dose (150 mg), with and without concomitant enteral feeding, will show a proportionate increase in bioavailability.</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Influenza A Virus Infection</condition>
  <condition>Influenza B Virus Infection</condition>
  <arm_group>
    <arm_group_label>A.Oseltamivir 75 mg dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Oseltamivir 150mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir 75 mg</intervention_name>
    <description>The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.</description>
    <arm_group_label>A.Oseltamivir 75 mg dose</arm_group_label>
    <arm_group_label>B. Oseltamivir 150mg</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients admitted to the Intensive Care Unit requiring mechanical ventilation due to
             respiratory failure

          -  must be within the ages of 18-75 yrs

        Exclusion Criteria:

          -  patients unable to have enteral feeding

          -  intolerance to oseltamivir

          -  pregnancy

          -  gastrointestinal or malabsorptive disease

          -  intestinal bypass surgery

          -  diarrhea (&gt;2 loose bowel movements per day)

          -  receipt of prokinetic medications (metoclopramide, domperidone, erythromycin)

          -  severe liver disease (hepatocellular enzymes &gt; 3 times the upper limit of normal)

          -  renal failure (Cockroft-Gault Creatinine Clearance &lt; 30 ml/min, Dialysis dependant)

          -  cystic fibrosis

          -  intoxication or drug overdose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal Siddiqui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>April 1, 2010</last_update_submitted>
  <last_update_submitted_qc>April 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Faisal Siddiqui MD</name_title>
    <organization>University of Manitoba</organization>
  </responsible_party>
  <keyword>Prevention or treatment of influenza in ventilated patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

